ANI's Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug Tranxene.
The current annual US market for Clorazepate Dipotassium Tablets is approximately USD 25.8m, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
ANI Pharmaceuticals is engaged in developing, manufacturing, and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need.
Its team is focused on delivering sustainable growth by building a successful Purified Cortrophin Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging its North American manufacturing capabilities.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT